account- Shares of Biogen Idec Inc. rocketed to an all-time high Thursday after the company said its oral multiple sclerosis drug candidate BG-12 cut relapses of the disease in half after two years of treatment. THE SPARK: Biogen Idec said patients who took...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Biogen surges on data for MS oral drug candidate
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account